Clinical Trials Directory

Trials / Completed

CompletedNCT07535424

Comparative Efficacy of Topical Clotrimazole Versus 2% Salicylic Acid in Otomycosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Mayo Hospital Lahore · Academic / Other
Sex
All
Age
5 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Otomycosis is a fungal infection of the outer ear canal that commonly causes itching, discomfort, discharge, and a feeling of blockage in the ear. This randomized controlled study was conducted to compare two commonly used topical treatments for otomycosis: clotrimazole ear drops and 2% salicylic acid ear drops. A total of 60 patients diagnosed with otomycosis were enrolled and were randomly assigned in equal numbers to one of the two treatment groups. One group received clotrimazole drops three times daily for two weeks, while the other group received 2% salicylic acid drops at the same frequency and for the same duration. Patients were assessed at the start of treatment and again after two weeks. The main outcome measure was relief of ear blockage, which reflected improvement in canal patency after treatment. It was hypothesized that topical clotrimazole would be more effective than 2% salicylic acid in clearing ear blockage and improving short-term clinical recovery in patients with otomycosis. This study was conducted to provide evidence for selecting an effective, practical, and affordable topical treatment for routine clinical use.

Conditions

Interventions

TypeNameDescription
DRUGclotrimazoleThree drops of clotrimazole were administered in the affected ear three times daily for two weeks.
DRUG2% Salicylic AcidThree drops of 2% salicylic acid were administered in the affected ear three times daily for two weeks.

Timeline

Start date
2024-11-20
Primary completion
2025-10-20
Completion
2025-10-20
First posted
2026-04-17
Last updated
2026-04-17

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07535424. Inclusion in this directory is not an endorsement.